Protein-Nanoparticle Interactions
暂无分享,去创建一个
Morteza Mahmoudi | L'Hocine Yahia | Nancy Tawil | Sophie Laurent | L. Yahia | M. Mahmoudi | S. Laurent | M. Rahman | N. Tawil | M. Mizanur Rahman | M. Rahman | Nancy Tawil
[1] M. Mahmoudi,et al. Protein-nanoparticle interactions: opportunities and challenges. , 2011, Chemical reviews.
[2] S. K. Sundaram,et al. Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.
[3] M. Mahmoudi,et al. Physiological temperature has a crucial role in amyloid β in the absence and presence of hydrophobic and hydrophilic nanoparticles. , 2013, ACS chemical neuroscience.
[4] V. Torchilin,et al. Which polymers can make nanoparticulate drug carriers long-circulating? , 1995 .
[5] P. Kehoe,et al. Interdisciplinary challenges and promising theranostic effects of nanoscience in Alzheimer's disease , 2012 .
[6] J. Brash,et al. Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma. , 2001, Biochimica et biophysica acta.
[7] P. Cullis,et al. β2-Glycoprotein I Is a Major Protein Associated with Very Rapidly Cleared Liposomes in Vivo, Suggesting a Significant Role in the Immune Clearance of "Non-self" Particles (*) , 1995, The Journal of Biological Chemistry.
[8] Janos Szebeni,et al. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. , 2005, Toxicology.
[9] Molly M. Stevens,et al. Exploring and exploiting chemistry at the cell surface. , 2011, Nature chemistry.
[10] R. Müller,et al. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparison of plasma protein adsorption patterns , 2005, Journal of drug targeting.
[11] Iseult Lynch,et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.
[12] P. Couvreur,et al. Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2‐DE, CE and Protein Lab‐on‐chip® system , 2007, Electrophoresis.
[13] S M Moghimi,et al. Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.
[14] J. Kamps,et al. The role of apolipoprotein E in the elimination of liposomes from blood by hepatocytes in the mouse. , 2005, Biochemical and biophysical research communications.
[15] James L. McGrath,et al. The influence of protein adsorption on nanoparticle association with cultured endothelial cells. , 2009, Biomaterials.
[16] Jan E. Schnitzer,et al. Caveolae: mining little caves for new cancer targets , 2003, Nature Reviews Cancer.
[17] E. Kosenko,et al. Effects of hydrated forms of C60 fullerene on amyloid 1-peptide fibrillization in vitro and performance of the cognitive task. , 2007, Journal of nanoscience and nanotechnology.
[18] Urs O. Häfeli,et al. Crucial Ignored Parameters on Nanotoxicology: The Importance of Toxicity Assay Modifications and “Cell Vision” , 2012, PloS one.
[19] Iseult Lynch,et al. The evolution of the protein corona around nanoparticles: a test study. , 2011, ACS nano.
[20] J. Lippincott-Schwartz,et al. New roles for endosomes: from vesicular carriers to multi-purpose platforms , 2009, Nature Reviews Molecular Cell Biology.
[21] Alexandra Kroll,et al. Testing Metal‐Oxide Nanomaterials for Human Safety , 2010 .
[22] Jianjun Cheng,et al. Protein corona significantly reduces active targeting yield. , 2013, Chemical communications.
[23] Morteza Mahmoudi,et al. Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell "vision" versus physicochemical properties of nanoparticles. , 2011, ACS nano.
[24] D. Simberg,et al. Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems , 2011, Expert opinion on drug delivery.
[25] R. Müller,et al. Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN). , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[26] H. Iwata,et al. Complement activation by polymers carrying hydroxyl groups. , 2009, ACS applied materials & interfaces.
[27] M. Mahmoudi,et al. Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer. , 2011, International journal of molecular epidemiology and genetics.
[28] Iseult Lynch,et al. Designing the nanoparticle-biomolecule interface for "targeting and therapeutic delivery". , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[29] Howard Riezman,et al. Proteasome-Independent Functions of Ubiquitin in Endocytosis and Signaling , 2007, Science.
[30] Morteza Mahmoudi,et al. Cell "vision": complementary factor of protein corona in nanotoxicology. , 2012, Nanoscale.
[31] The effects of aggregation and protein corona on the cellular internalization of iron oxide nanoparticles. , 2011, Biomaterials.
[32] C. Hunt,et al. Murine plasma fibronectin depletion after intravenous injection of liposomes , 1987 .
[33] Parag Aggarwal,et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.
[34] R. Weissleder,et al. Uptake of dextran‐coated monocrystalline iron oxides in tumor cells and macrophages , 1997, Journal of magnetic resonance imaging : JMRI.
[35] Philip M. Kelly,et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. , 2013, Nature nanotechnology.
[36] M. Foote. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. , 2007, Biotechnology annual review.
[37] R. Müller,et al. 'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. , 2000, Colloids and surfaces. B, Biointerfaces.
[38] M. Dobrovolskaia,et al. Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.
[39] Morteza Mahmoudi,et al. Assessing the in vitro and in vivo toxicity of superparamagnetic iron oxide nanoparticles. , 2012, Chemical reviews.
[40] M. Morandi,et al. Nanoparticle‐induced platelet aggregation and vascular thrombosis , 2005, British journal of pharmacology.
[41] Jayanth Panyam,et al. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.
[42] J. Eaton,et al. Albumin-binding surfaces for implantable devices. , 1992, Journal of biomedical materials research.